Brokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) PT at $38.25

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have received a consensus recommendation of "Hold" from the fourteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $38.25.

Several analysts recently weighed in on the company. Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Morgan Stanley cut Hims & Hers Health from an "overweight" rating to an "equal weight" rating and increased their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Needham & Company LLC increased their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Finally, Bank of America boosted their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a report on Tuesday, March 18th.

Hims & Hers Health Trading Up 5.3 %

Hims & Hers Health stock traded up $1.41 during trading hours on Friday, reaching $28.12. 3,618,868 shares of the company were exchanged, compared to its average volume of 15,466,554. Hims & Hers Health has a 12 month low of $11.20 and a 12 month high of $72.98. The stock has a 50-day moving average of $35.50 and a 200 day moving average of $30.78. The firm has a market cap of $6.25 billion, a price-to-earnings ratio of 63.72 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, research analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 100,000 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $35.22, for a total value of $3,522,000.00. Following the transaction, the chief executive officer now owns 27,918 shares of the company's stock, valued at approximately $983,271.96. The trade was a 78.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Chi sold 17,304 shares of the firm's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $31.00, for a total value of $536,424.00. Following the completion of the sale, the insider now owns 193,601 shares of the company's stock, valued at approximately $6,001,631. This trade represents a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 730,302 shares of company stock worth $28,528,874 over the last three months. 17.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC bought a new position in Hims & Hers Health in the 3rd quarter worth approximately $207,000. MML Investors Services LLC acquired a new stake in shares of Hims & Hers Health in the 3rd quarter valued at $197,000. Barclays PLC raised its position in shares of Hims & Hers Health by 9.7% during the third quarter. Barclays PLC now owns 308,363 shares of the company's stock worth $5,680,000 after acquiring an additional 27,231 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock valued at $79,029,000 after acquiring an additional 482,177 shares during the period. Finally, Sanctuary Advisors LLC boosted its holdings in Hims & Hers Health by 26.8% in the third quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company's stock valued at $480,000 after acquiring an additional 5,505 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.